Leerink Partners Remain Bullish on Seattle Genetics (SGEN) Following FDA's Approval of Adcetris
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Needham & Company Reiterate Buy on Seattle Genetics (SGEN) Following Adcetris Approval
August 18, 2015 11:12 AM EDTNeedham & Company reiterated a Buy rating and $60.00 price target on Seattle Genetics (NASDAQ: SGEN) following the announced approval of Adcetris in Hodgkin's Lymphoma patients with high risk for relapse after stem cell transplant. Approval in this indication was based on the AETHERA... More
Pre-Open Stock Movers 08/18: (OMER) (ESPR) (SUNE) (DKS) (HD) Higher; (APP) (SNDK) (WMT) Lower (more...)
August 18, 2015 9:30 AM EDTOmeros (NASDAQ: OMER) 64.4% HIGHER; announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) aggregations of platelets in the... More
Seattle Genetics (SGEN) Announces FDA Approval of ADCETRIS as Classical HL Treatment in Certain Patients
August 17, 2015 4:10 PM EDTSeattle Genetics (NASDAQ: SGEN) announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the treatment of patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation. The approval is based on a phase 3 clinical trial called AETHERA that was designed to compare up to 16 cycles (approximately one year) of ADCETRIS therapy administered every three weeks following auto-HSCT to placebo. The primary endpoint was met with a significant improvement in median progression-free survival (PFS) of 42.9 months (95% CI: 30.4, 42.9) for... More
